Mylan Has Green Light On Remdesivir
Follows Cipla And Hetero Launches Of COVID-19 Treatment
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
You may also be interested in...
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”
Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.